Our healthcare consulting clients have generated over $19 Billion in market capitalization with 9 IPOs, and over $500 Million of venture capital funding!
We helped our clients create several new market categories with billion-dollar markets size with scalable "out of the box" business models to establish long term leadership.
As first advisor and investor in Omada Health, Anne helped create one of the leaders in digital therapeutics for chronic diseases and ...unicorn in the making!
As acting VP Sales and Marketing of Advanced Sterilization Products (ASP), an intrapreneurship initiative within J&J, Anne built the launch program of STERRAD, a revolutionary sterilization system, that was ultimately sold for $2.7 billion in 2018
As advisor to the founder and CEO of Masimo , Anne fine tuned the business model and marketing strategy for this second generation pulse oximetry. Masimo went public in 2007 (NASDAQ: MASI) and has a $8 Billion market cap.
Anne worked closely with the VISICU founding physicians to refine their original concept to a scalable business. She was one of the first angel investors.Visicu went public in 2006 and was acquired by Phillips Medical for $440 Million.
Anne advised CooperVision in spinning off VISX to develop their excimer laser vision for the LASIK correction system. She helped the founders with business strategy and fundraising. VISX went public in 1989 sold for $1.3 Billion , and now within J&J
Anne was an active advisor to Omnicell and then joined as the founding VP of marketing . She was instrumental in growing the business from zero to $50 million in three years. The company went public in 2001 (NASDAQ: OMCL) and has a $3.4 Billion market cap.
Anne DeGheest was an active advisor to the founders and investors of Thermage, a non invasive RF therapy. Thermage went public in 2006 and became Solta Medical after merging with Reliant Technology. Valeant acquired them for $250 Million.
Anne worked with Aspect Medical two founders to raise venture capital and develop a new brain function monitor. Aspect medical went public in 2000 (NASDAQ: ASPM) and was acquired for $210 Million by Covidien /Medtronic
Anne led a syndication with corporate ventures investors to fund CareInSync, a patient care coordination app for hospital providers that was acquired by Zynx Health (part of Hearst Health)
Anne worked closely with the Pyxis founders to turn them around and redefine the MedStation, a hospital drug dispensing systems. Pyxis went public in 1992 and was acquired by Cardinal for around $1 billion and is now part of BD.
Anne worked with Dr. Susan Love and other founders of the FirstCyte™ Breast Test to evaluate breast cancer risk in the milk ducts. Pro-Duct Health was acquired by Cytyc for $167 Million. Now Hologic.
In 2007, Anne led Life Science Angels into an investment into Textronics, one of the first smart textile wearable, to measure heart rate. Adidas acquired Textronics.
Bob wrote Affymetrix first marketing plan for DNA chip use in diagnostics and infectious disease. He was instrumental in defending its patent claims. Affymetrix went public and was acquired by Thermo Fisher for $1.3 Billion
Bob was the founding CEO of Protogene that became the first company to commercialize chip synthesis of DNA oligos using ink jet printing devices and becoming the world’s largest manufacturer of custom DNA. Retrotope was successfully sold to Life Technologies, now part of Thermo Fisher.
Bob consulted with Sequenom’s founders and wrote the first business plan based on commercial sequence identification using mass spectrometry. Sequenom became a leading molecular diagnostics company, went public and was acquired by Lab Corp for $302 Million.